Breaking News

Patient-reported outcomes from a multicenter, randomized, controlled trial of MASO63DP in mild to moderate adult atopic dermatitis

Patient-reported outcomes from a multicenter, randomized, controlled trial of MASO63DP in mild to moderate adult atopic dermatitis

 
 

A 50-day, multicenter, randomized, double-blind, vehicle-controlled study in 218 adults with mild to moderate atopic dermatitis (AD) assessed the efficacy and tolerability of MASO63DP, a nonsteroidal cream. The Patient Global Assessment (PGA) change from baseline was conducted on days 8, 22, 36 and 50. Patient total body itching was measured by visual analogue scale and patient opinion on treatment acceptability was also determined. More MASO63DP patients had improvement in PGA scores and total body itch versus controls (p < 0.0001). At day 22, 77% of the active group had good improvement or better versus 21% of controls. Similarly, 78% had an assessment of good improvement or total resolution versus 29% of vehicle-treated patients. ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list